CRISPR-Cas9 Gene Editing: Promising Therapeutics for HPV-driven Cervical Cancer

References

1. Wang R. Pan W. Jin L. Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Lett. 2020 471 88 102 10.1016/j.canlet.2019.11.039 31812696
   [Google Scholar]
2. Liu B. Zhou H. Tan L. Siu K.T.H. Guan X.Y. Exploring treatment options in cancer: Tumor treatment strategies. Signal Transduct. Target. Ther. 2024 9 1 175 10.1038/s41392‑024‑01856‑7 39013849
   [Google Scholar]
3. Yousefi Z. Aria H. Ghaedrahmati F. An update on human papilloma virus vaccines: History, types, protection, and efficacy. Front. Immunol. 2022 12 805695 10.3389/fimmu.2021.805695 35154080
   [Google Scholar]
4. Dey T. Agrawal S. Immunotherapy in cervical cancer: An innovative approach for better treatment outcomes. Explor Target Antitumor Ther 2025 6 1002296 10.37349/etat.2025.1002296 40061136
   [Google Scholar]
5. Ketch P.W. Zaharias R.S. Leath C.A. Pharmacotherapy for cervical cancer: Current standard of care and new perspectives. Expert Opin. Pharmacother. 2024 25 12 1591 1603 10.1080/14656566.2024.2395379 39164924
   [Google Scholar]
6. Amjad E. Pezzani R. Sokouti B. A review of the literature on the use of CRISPR/Cas9 gene therapy to treat hepatocellular carcinoma. Oncol. Res. 2024 32 3 439 461 10.32604/or.2023.044473 38361756
   [Google Scholar]
7. Biederstädt A. Manzar G.S. Daher M. Multiplexed engineering and precision gene editing in cellular immunotherapy. Front. Immunol. 2022 13 1063303 10.3389/fimmu.2022.1063303 36483551
   [Google Scholar]
8. Chehelgerdi M. Chehelgerdi M. Khorramian-Ghahfarokhi M. Comprehensive review of CRISPR-based gene editing: Mechanisms, challenges, and applications in cancer therapy. Mol. Cancer 2024 23 1 9 10.1186/s12943‑023‑01925‑5 38195537
   [Google Scholar]
9. Skalickova M. Hadrava Vanova K. Uher O. Injecting hope: The potential of intratumoral immunotherapy for locally advanced and metastatic cancer. Front. Immunol. 2025 15 1479483 10.3389/fimmu.2024.1479483 39850897
   [Google Scholar]
10. Wei Y. Zhao Z. Ma X. Description of CRISPR-Cas9 development and its prospects in human papillomavirus-driven cancer treatment. Front. Immunol. 2022 13 1037124 10.3389/fimmu.2022.1037124 36479105
    [Google Scholar]
11. Shah S.S.T.H. CRISPR-Cas9: An evolutionary technique for the treatment of breast and cervical carcinoma. Asian Pac J Environ Cancer 2024 7 1 85 93 10.31557/apjec.2024.7.1.85‑93
    [Google Scholar]
12. Gao C. Wu P. Yu L. The application of CRISPR/Cas9 system in cervical carcinogenesis. Cancer Gene Ther. 2022 29 5 466 474 10.1038/s41417‑021‑00366‑w 34349239
    [Google Scholar]
13. Li L. Hu S. Chen X. Non-viral delivery systems for CRISPR/Cas9-based genome editing: Challenges and opportunities. Biomaterials 2018 171 207 218 10.1016/j.biomaterials.2018.04.031 29704747
    [Google Scholar]
14. Duan L. Ouyang K. Xu X. Nanoparticle delivery of CRISPR/Cas9 for genome editing. Front. Genet. 2021 12 673286 10.3389/fgene.2021.673286 34054927
    [Google Scholar]
15. Rauf M.A. Rao A. Sivasoorian S.S. Iyer A.K. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment: A comprehensive review. Cells 2025 14 15 1136 10.3390/cells14151136 40801569
    [Google Scholar]
16. Seijas A. Cora D. Novo M. Al-Soufi W. Sánchez L. Arana Á.J. CRISPR/Cas9 delivery systems to enhance gene editing efficiency. Int. J. Mol. Sci. 2025 26 9 4420 10.3390/ijms26094420 40362657
    [Google Scholar]
17. Kermanshahi A.Z. Ebrahimi F. Taherpoor A. Eslami N. Baghi H.B. HPV-driven cancers: A looming threat and the potential of CRISPR/Cas9 for targeted therapy. Virol. J. 2025 22 1 156 10.1186/s12985‑025‑02783‑x 40400023
    [Google Scholar]
18. Li C. Yang T. Weng Y. Ionizable lipid-assisted efficient hepatic delivery of gene editing elements for oncotherapy. Bioact. Mater. 2022 9 590 601 10.1016/j.bioactmat.2021.05.051 34853819
    [Google Scholar]
19. Kozovska Z. Rajcaniova S. Munteanu P. Dzacovska S. Demkova L. CRISPR: History and perspectives to the future. Biomed. Pharmacother. 2021 141 111917 10.1016/j.biopha.2021.111917 34328110
    [Google Scholar]
20. Chen M. Mao A. Xu M. Weng Q. Mao J. Ji J. CRISPR-Cas9 for cancer therapy: Opportunities and challenges. Cancer Lett. 2019 447 48 55 10.1016/j.canlet.2019.01.017 30684591
    [Google Scholar]
21. Youssef E. Fletcher B. Palmer D. Enhancing precision in cancer treatment: The role of gene therapy and immune modulation in oncology. Front. Med. 2025 11 1527600 10.3389/fmed.2024.1527600 39871848
    [Google Scholar]
22. A safety and efficacy study of TALEN and CRISPR/Cas9 in the treatment of HPV-related cervical intraepithelial Neoplasia 2017 NCT03057912 Available from: https://clinicaltrials.gov/study/NCT03057912
23. Bulcha J.T. Wang Y. Ma H. Tai P.W.L. Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct. Target. Ther. 2021 6 1 53 10.1038/s41392‑021‑00487‑6 33558455
    [Google Scholar]